General
publicado em 18/09/2012 às 14h59:00
   Dê o seu voto:

Brazil and France test new treatment for HIV with tuberculosis

Results have been promising, with new antiretroviral regimen was effective and safe for treating patients

 
font size
A-
A+

Some pieces of information on this page may have been automatically translated. Makernews is not responsible for the irregularities resulting from these translations. When in doubt,      consult the original text.



Foto: Fiocruz
Groups participating in the tests for 48 weeks and received concomitant treatment for tuberculosis
  « Previous
next »  
Groups participating in the tests for 48 weeks and received concomitant treatment for tuberculosis

Researchers at the Clinical Research Institute Evandro Chagas (IPEC / Fiocruz), in partnership with the French National Agency for Research on AIDS and Viral Hepatitis (ANRS), the Ministry of Health and research centers in Brazil and in France tested an antiretroviral regimen containing Raltegravir drug belonging to the class of drugs called integrase inhibitors, as compared to that containing efavirenz. Results of tests show that the inhibitor regimen with demonstrated efficacy and safety for treating HIV-infected with tuberculosis.

According to infectologist Fiocruz and study coordinator in Brazil, Beatriz Grinsztejn, the results point to the possibility of the use of the inhibitor as an alternative to efavirenz. The Raltegravir has a good tolerability profile and is easy to be taken, he said. The study, which is in phase two, involving 155 HIV-positive in tuberculosis treatment based on Rifampicin. Participants were divided into three groups, the first of which received a standard dose of raltegravir (400 mg twice daily), the second a double dose of the drug and the third the usual dose of efavirenz. Three groups participated in the tests for 48 weeks and received concomitant treatment for tuberculosis. To Grinsztejn, findings indicate the completion of a larger study, phase three, so that final results can be achieved. Our expectation for the next steps is optimistic he says.

Tuberculosis is the leading cause of death among HIV-positive and, like AIDS, affecting mainly developing countries, where a growing number of patients with both diseases. Rifampicin is one of the basic components used to combat tuberculosis, but interacts with many of the antiviral drugs used to treat HIV infection, which can lead to difficulties in the treatment of co-infected patients. The Efavirenz in combination with drug tenofovir (TDF) and lamivudine (3TC), comprises the antiretroviral regimen used in the initial treatment of these patients. However, there is still no alternative scheme aimed at individuals with intolerance to Efavirenz and women in early pregnancy, the use of which is restricted by the risk of harm to the fetus.

Source: Isaude.net
   Palavras-chave:   AIDS    HIV    Instituto Evandro Chagas Clinical Research    IPEC    Fiocruz    Brazil    France   
  • Share this pageShare this page
  • Share this pageCorrect
  • ShareShare
  • AlertAlert
Reduced link: 
  • You are recommending this story: Brazil and France test new treatment for HIV with tuberculosis
  • Fill in the following form to send your recommendation to your friend:

  • You are suggesting a correction for this story: Brazil and France test new treatment for HIV with tuberculosis


Receba notícias do iSaúde no seu e-mail de acordo com os assuntos de seu interesse.
Seu nome:
Seu email:
Desejo receber um alerta com estes assuntos:
AIDS    HIV    Instituto Evandro Chagas Clinical Research    IPEC    Fiocruz    Brazil    France   
Comments:
Comment
Leave your comment
Close
(Required fields are marked with an *)

(Your email address will never be published or shared.)

Enter the letters and numbers below and click in the button "send"

  • Twitter iSaúde
advertising
Informe Saúde printed version

Recommend the portal
Close [X]
  • You are recommending this story: http://www.isaude.net
  • Fill in the following form to send your recommendation to your friend:

RSS news from the portal  iSaúde.net
Get the newsletter of the portal  iSaúde.net
Recommend the portal iSaúde.net
News from  iSaúde.net in your blog or website.
Get news on the subject of your interest.
© 2000-2011 www.isaude.net Todos os direitos reservados.